Vasomotor Symptoms Clinical Trial
Official title:
A Phase 1 Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of GS1-144 Tablets
The primary purpose of this study is to assess the safety and tolerability of single ascending doses of GS1-144 in healthy participants in Part 1 and to assess the safety and tolerability of multiple ascending doses of GS1-144 in healthy postmenopausal female participants in Part 2.
Status | Recruiting |
Enrollment | 68 |
Est. completion date | December 17, 2024 |
Est. primary completion date | December 17, 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. At the time of signing the informed consent form (ICF): Part 1 only: healthy male and female participants aged between 18 and 45 years inclusive; Part 2 only: healthy women aged between 40 and 65 years inclusive who have undergone natural menopause; 2. Body weight >=50 kilogram (kg) (male), >=45 kg (female) with a body mass index between 18.0 and 32.0 kilogram per square meter (kg/m^2) inclusive at screening; 3. Part 1 only: Female participants are eligible to participate if they are not pregnant, not breastfeeding, and highly effective contraception includes placement of an intrauterine device or intrauterine system plus use of a condom; 4. Part 1 only: Male participants must agree to practice true abstinence; be surgically sterilized; or agree to use a condom plus effective contraception for their female partner, if of childbearing potential, from screening and for at least 90 days after dosing and refrain from donating sperm during this period. These contraception requirements do not apply if the male participant is in an exclusively same sex relationship; 5. Able to comprehend the nature of the study and any risks associated with participation and willing to cooperate and comply with protocol restrictions and requirements. Exclusion Criteria: 1. Any known allergy to the components or analogues of the investigational product, or those with an allergic constitution; 2. A history of currently suffering from any other cardiovascular, gastrointestinal, endocrine, hematological, hepatic, immunological, metabolic, urinary, pulmonary, neurological, dermatological, psychiatric, renal and/or other major diseases deemed clinically significant by the investigator; 3. Known/confirmed history of malignancy; 4. A history of epileptic seizure or increased risk of epileptic seizure, or participants with a recent history of head trauma leading to loss of consciousness or concussion; 5. A history of currently suffering from hypothalamic dysfunction; 6. Significant acute/chronic infections within two weeks prior to dosing; 7. Undergone major surgical procedures within six months prior to screening or plan to undergo any surgery during the trial; 8. Participated in other clinical trials within 1 month prior to dosing; 9. Have lost or donated more than 400 mL of blood within 1 month prior to screening; 10. Have taken any prescription/over-the-counter drugs or dietary supplements within 7 days prior to dosing or within 5 halflives of the drug; 11. Clinically significant abnormalities on physical examination or genitourinary ultrasound at the time of screening; 12. Clinically significant abnormalities in vital signs; 13. Prolonged QTcF interval in 12-lead ECG results ; 14. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), total bilirubin (TBIL), blood creatinine (CRE), blood urea nitrogen (BUN), or international normalized ratio (INR) higher than the upper limit of normal (ULN) at screening, that are considered as clinically significant abnormalities by the investigator; 15. Part 2 only: abnormal sex hormone levels at screening that are considered clinically significant by the investigator; 16. Clinically significant abnormalities in thyroid function, parathyroid function, and neck ultrasound results at screening; 17. Women with positive pregnancy test result or those who are breastfeeding before dosing; 18. Positive hepatitis C virus antibody (HCV Ab), positive human immunodeficiency virus antibody (HIV Ab) or positive hepatitis B surface antigen (HbsAg) result at screening; 19. Unable to refrain from consuming grapefruit, pomelo, grapefruit juice, or pomelo juice from 48 hours prior to check-in until the end of the study; 20. Unable to refrain from consuming any foods or beverages containing caffeine or xanthine from 48 hours prior to check-in until the end of the study; 21. Unable to abstain from smoking/using tobacco products from 48 hours prior to check-in until the end of the study; 22. Unable to refrain from consuming alcohol from 48 hours prior to check-in until the end of the study; 23. Any history of narcotic use or drug abuse; 24. Any medical or other condition may affect the clinical trial. |
Country | Name | City | State |
---|---|---|---|
Australia | Linear Clinical Research | Perth | Western Australia |
Lead Sponsor | Collaborator |
---|---|
Changchun GeneScience Pharmaceutical Co., Ltd. | Syneos Health |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Part 1: Number of Participants With Treatment -Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) | Number of participants with TEAEs and SAEs will be reported. | Up to Day 4 | |
Primary | Part 2:Number of Participants With TEAEs and SAEs | Number of female post-menopausal participants with TEAEs and SAEs will be reported. | Up to Day 12 | |
Secondary | Parts 1 and 2: AUC0-t- Area Under the Drug Concentration-time Curve From Time 0 to the Last Sample Collection Time t for GS1-144 | AUC0-t will be assessed and reported. | Part 1 Day 1- pre-dose and up to 24 hour post-dose; Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose | |
Secondary | Parts 1 and 2: AUC0-infinity- Area Under the Drug Concentration-time Curve From 0 to Infinity for GS1-144 | AUC0-infinity will be assessed and reported. | Part 1 Day 1- pre-dose and up to 24 hour post-dose; Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose | |
Secondary | Parts 1 and 2: Cmax- Maximum Observed Plasma Concentration for GS1-144 | Cmax will be assessed and reported. | Part 1 Day 1- pre-dose and up to 24 hour post-dose; Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose | |
Secondary | Parts 1 and 2: Tmax- Time to Reach the Maximum Plasma Concentration (Cmax) for GS1-144 | Tmax will be assessed and reported. | Part 1 Day 1- pre-dose and up to 24 hour post-dose; Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose | |
Secondary | Parts 1 and 2: T1/2- Terminal Half-life for GS1-144 | T1/2 will be assessed and reported. | Part 1 Day 1- pre-dose and up to 24 hour post-dose; Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose | |
Secondary | Parts 1 and 2: CL/F- Apparent Clearance for GS1-144 | CL/F will be assessed and reported. | Part 1 Day 1- pre-dose and up to 24 hour post-dose; Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose | |
Secondary | Parts 1 and 2: Vd/F- Apparent Volume of Distribution for GS1-144 | Vd/F will be assessed and reported. | Part 1 Day 1- pre-dose and up to 24 hour post-dose; Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose | |
Secondary | Part 2: Cmax,ss- Observed Maximum Concentration at Steady State for GS1-144 | Cmax at steady state will be assessed and reported. | Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose | |
Secondary | Part 2: Cmin,ss- Observed Minimum Concentration at Steady State for GS1-144 | Cmin at steady state will be assessed and reported. | Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose | |
Secondary | Part 2: Tmax,ss- Time of Cmax at Steady State for GS1-144 | Tmax at steady state will be assessed and reported. | Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose | |
Secondary | Part 2: Cavg,ss- Average Concentration at Steady State for GS1-144 | Cavg at steady state will be assessed and reported. | Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose | |
Secondary | Part 2: AUC0-t- Area Under the Drug Concentration-time Curve During the Dosing Interval at Steady State for GS1-144 | AUC0-T at steady state will be assessed and reported. | Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose | |
Secondary | Part 2: CLss/F- CL for Bioavailability at Steady State for GS1-144 | CL/F at steady state will be assessed and reported. | Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose | |
Secondary | Part 2: T1/2,ss- Terminal Half-life at Steady State for GS1-144 | T1/2 at steady state will be assessed and reported. | Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose | |
Secondary | Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose | Accumulation Ratio will be assessed and reported. | Part 2 Days 1 and 7-pre-dose and up to 30 hour post-dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04090957 -
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women
|
Phase 3 | |
Completed |
NCT01052454 -
Mindfulness-Based Stress Reduction for Hot Flashes
|
Phase 0 | |
Completed |
NCT00535288 -
Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)
|
Phase 3 | |
Recruiting |
NCT00906308 -
A Study of MF101 in Postmenopausal Women
|
Phase 3 | |
Completed |
NCT01452373 -
Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women
|
Phase 3 | |
Completed |
NCT00560833 -
Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)
|
Phase 3 | |
Completed |
NCT05033886 -
A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause
|
Phase 3 | |
Completed |
NCT05083884 -
A Survey About Hot Flashes in Women Going Through the Menopause
|
||
Completed |
NCT01178892 -
MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation
|
N/A | |
Completed |
NCT00397176 -
Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women
|
Phase 1 | |
Recruiting |
NCT06122181 -
Study of HS-10384 in Participants of Chinese Postmenopausal Women
|
Phase 1 | |
Not yet recruiting |
NCT06393673 -
A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women
|
Phase 2 | |
Withdrawn |
NCT02202707 -
Vasomotor Symptoms and Cardiovascular Control
|
N/A | |
Completed |
NCT00356447 -
Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.
|
Phase 3 | |
Completed |
NCT05312567 -
FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms
|
Phase 2 | |
Terminated |
NCT01353963 -
Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients
|
Phase 4 | |
Completed |
NCT00446199 -
Low-dose Hormone Therapy for Relief of Vasomotor Symptoms
|
Phase 3 | |
Completed |
NCT05850338 -
Determination of the Effects of Autogenic Relaxation Exercise and Cold Pillow Application on Vasomotor Symptom Control and Quality of Life in Postmenopausal Women
|
N/A | |
Completed |
NCT02803268 -
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms
|
Phase 1 | |
Completed |
NCT00683800 -
Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women
|
Phase 3 |